Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced financial results and business highlights for the third quarter of 2014. Navidea reported total revenue for third quarter 2014 of $2.3 million including Lymphoseek® (technetium Tc 99m tilmanocept) injection sales revenue of $1.1 million, $300,000 of Lymphoseek milestone revenue and $849,000 of grant and other revenue.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
